CLINICAL_TRIALS
trial_result
· 2026-02-04
Clinical Trial Update: Trial of Taselisib in Overgrowth [Phase 1, Phase 2]
Summary
A phase 1/2 trial of taselisib for PIK3CA-related overgrowth has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: PIK3CA-Related Overgrowth | Phase 1, Phase 2 | Status: TERMINATED